RIGL sucht den Boden zum Rebound... - 500 Beiträge pro Seite

[nkelchen]

neben NABI, PCYC und SCLN ein Kandidat auf den Rebound -
Achtung: hohes Risiko!

nk

[nkelchen]

[posting]19.794.400 von nkelchen am 20.01.06 00:25:07[/posting]

Rigel to Receive $5 Million Milestone Payment from Serono for R763
1/26/2006 7:31:11 AM










SOUTH SAN FRANCISCO, Calif., Jan 26, 2006 /PRNewswire-FirstCall via COMTEX/ -- Rigel Pharmaceuticals, Inc. (RIGL) announced today that it will receive a $5 million milestone payment from Serono triggered by the progress on the Investigational New Drug (IND) application for R763, for which Phase I clinical trials in cancer patients shall commence later this year. R763 is a highly potent, orally available multi-Aurora kinase inhibitor. Serono licensed development and commercialization rights to Rigel`s Aurora kinase inhibitor program, including R763 for cancer, in October 2005.







MARKETWATCH TOP NEWS
U.S. durable-goods orders rise 1.3% in December
GM reports $4.8 billion loss for fourth quarter
AT&T profit rises on wireless, DSL
Honeywell profit doubles; revenue up 10%
Eli Lilly`s quarterly profit boosted by newer products


TRACK THESE TOPICS
Alerts
Company: Rigel Pharmaceuticals Inc
Create

Get Breaking News sent directly to your inbox




Create An Alert

R763 has been shown in vitro and in in vivo tumor xenograft models to potently inhibit proliferation and trigger apoptosis in several leukemia and tumor cell lines including the cervix, colon, lung, pancreas and prostate.

"This is an important milestone for our collaboration with Serono, who will take R763 into clinical development in 2006. Given the broad applicability R763 has demonstrated on many types of solid tumors and leukemias, we`re excited to see this compound move further along in development," said Donald G. Payan, M.D., executive vice president and chief scientific officer of Rigel.

On October 25, 2005, Rigel announced that it had granted Serono an exclusive license to develop and commercialize product candidates from Rigel`s Aurora kinase inhibitor program. The license is worldwide, except for Japan, which Serono has an option to include at any time within two years following signature of the agreement. Under the terms of the agreement, Rigel is eligible to receive up to $160 million in total as well as royalties on any eventual product sales of R763 and other Aurora kinase inhibitors developed under the agreement. Serono will be responsible for the further development and commercialization of R763, as well as any other product candidates arising from Rigel`s Aurora kinase inhibitor program. Rigel has achieved milestones for total payments of $30 million from Serono to date, including $10 million in initial payments, $15 million in equity participation and this $5 million milestone payment for the IND.

Aurora Kinase and Cancer

The over-expression of Aurora kinase can cause cells to rapidly develop an abnormal number of chromosomes. Elevated levels of Aurora kinase are frequently associated with various human cancers, such as cancers of the breast, bladder, colon, ovary, head and neck, and pancreas. Inhibition of Aurora kinase arrests cell division and promotes programmed cell death (apoptosis). Increased knowledge of Aurora kinase and its regulation may result in future treatments for cancer.

Rigel`s lead oncology drug candidate, R763, is a highly potent inhibitor of Aurora kinase, which has been shown to potently inhibit proliferation and trigger apoptosis in several tumor cell lines including cervix, colon, lung, pancreas and prostate. Rigel discovered R763 using its proprietary cell-based PAD (Proliferation, Apoptosis and DNA content) assays applied to tumor cell lines.

About Rigel (www.rigel.com)

Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases, cancer and viral diseases. Our goal is to move one new product candidate for a significant indication into the clinic each year. We have achieved this goal since 2002. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel`s productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. We have product development programs in allergy/asthma, rheumatoid arthritis and cancer.

This press release contains "forward-looking" statements, including statements related to Rigel`s plans to pursue clinical development of product candidates and the timing thereof and the potential efficacy of product candidates. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "plans," "intends," "expects" and similar expressions are intended to identify these forward-looking statements. There are a number of important factors that could cause Rigel`s results to differ materially from those indicated by these forward-looking statements, including risks associated with the timing and success of pre-clinical studies and clinical trials, as well as other risks detailed from time to time in Rigel`s SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2005. Rigel does not undertake any obligation to update forward-looking statements.

Contact: Raul Rodriguez
Phone: [phone]
Email: [e-mail]

Media Contact: Carolyn Bumgardner Wang, WeissComm Partners, Inc.
Phone: [phone]
Email: [e-mail]


SOURCE Rigel Pharmaceuticals, Inc.

Raul Rodriguez of Rigel Pharmaceuticals, Inc., [phone], or [e-mail];
or press, Carolyn Bumgardner of Wang, WeissComm Partners, Inc., [phone], or
[e-mail], for Rigel Pharmaceuticals


http://www.prnewswire.com


Copyright (C) 2006 PR Newswire. All rights reserved.

[nkelchen]

[posting]19.895.320 von nkelchen am 26.01.06 18:00:27[/posting]

sieht eher be...en aus.



nk

[nkelchen]

[posting]19.920.940 von nkelchen am 27.01.06 22:56:25[/posting]

schon wieder im Aufwind!?

Rigel Achieves Milestone with Merck Ligase Collaboration
1/30/2006 7:30:38 AM



SOUTH SAN FRANCISCO, Calif., Jan 30, 2006 /PRNewswire-FirstCall via COMTEX/ -- Rigel Pharmaceuticals, Inc. (RIGL) announced today that it has received a milestone payment from Merck & Co., Inc. (MRK) as part of their collaboration to investigate ubiquitin ligases, a new class of drug targets, to find treatments for cancer and potentially other diseases.


nk
*zumindest der Chart hat sich verbessert*

[nkelchen]

[posting]19.982.550 von nkelchen am 31.01.06 21:27:26[/posting]

sieht doch wieder richtig gut aus..

Ein SK über 8 muss noch her, dann Angriff auf die 8,30


nk

[nkelchen]

[posting]19.994.664 von nkelchen am 01.02.06 16:24:04[/posting]

gesagt, getan....

SK über 8,30 und ich bin rundherum zufrieden!

nk

[nkelchen]

[posting]20.030.944 von nkelchen am 03.02.06 16:07:16[/posting]

Rigel to Present at Upcoming Scientific Conferences
2/1/2006 7:30:42 AM



SOUTH SAN FRANCISCO, Calif., Feb 01, 2006 /PRNewswire-FirstCall via COMTEX/ -- Rigel Pharmaceuticals, Inc. (RIGL) today announced that it will be presenting at two upcoming scientific conferences. Details are as follows: ...

[nkelchen]

[posting]20.062.798 von nkelchen am 06.02.06 13:43:17[/posting]

Quotes & News:
symbol/fund/keyword
Quote/Chart/NewsProfileNews SearchInteractive ChartingAnalyst EstimatesInsider TradingFinancialsOption ChainSEC FilingsDiscussionHistorical QuoteIndustry AnalysisChoose Your Broker- - - - - -Market AdvisersFree Annual ReportNewsletter Directory Find symbol Search News Site Index

Rigel Pharmaceuticals Inc (NASDAQ NM) Chart Financial Analyst Insider Msg News Option SEC


RIGL 8.37 +0.13 +1.58% Vol:252,300 12:00am 02/06/06

SPONSORED LINKS Get listed here


Mortgage Rates Hit Record Lows! - Compare free mortgage rate quotes. Refinance today and save thousands. Fast and simple ...

$150,000 Mortgage for $483/Month - Compare up to 4 free offers. Refinance and save $1,000`s! All credit types accepted.

Triple Your Money With This Stock Pick - New hot stock picks every week on issues with explosive growth potential. Underva...

Build A Stronger Portfolio - Top performing portfolios through innovative investment technology. Portfolio, email trade ale...





Rigel Announces Fourth Quarter and Year End 2005 Financial Results
2/7/2006 7:31:09 AM










SOUTH SAN FRANCISCO, Calif., Feb 07, 2006 /PRNewswire-FirstCall via COMTEX/ -- Rigel Pharmaceuticals, Inc. (RIGL) today reported financial results for the fourth quarter and year ended December 31, 2005.







MARKETWATCH TOP NEWS
GM chief to speak; dividend reportedly will be cut
BP profit rises 22% on oil prices, refining services
Portugal Telecom soars on Sonae`s $12.8 billion offer
Disney shares gain as earnings beat expectations
Polo Ralph Lauren profit up 20%; view cut on charges

For the fourth quarter of 2005, Rigel reported a net loss of $8.9 million, or $0.36 per share, compared to a net loss of $14.7 million, or $0.75 per share, in the fourth quarter of 2004. Weighted average shares outstanding for the fourth quarters of 2005 and 2004 were 24.5 million and 19.5 million, respectively.

Rigel reported revenue from collaborations of $6.0 million in the fourth quarter of 2005, compared to $1.1 million in the fourth quarter of 2004. Revenue in the fourth quarter of 2005 reflects the amortization of the upfront payments by Serono, Pfizer and Merck as well as additional revenue from Merck for research reimbursement and a milestone payment.

Total operating expenses were $16.1 million in the fourth quarter of 2005, compared to operating expenses of $16.0 million in the fourth quarter of 2004. Increases in operating expenses in the fourth quarter of 2005 were offset by the inclusion of $2.2 million of stock-based compensation recovery compared to an expense during the same period last year of $168,000. Increases in expenses in the fourth quarter of 2005 were primarily due to the completion and analysis of the Phase II R112 study in allergic rhinitis, preparation and filing of an investigational new drug (IND) application for R763, an Aurora kinase inhibitor, and ongoing studies with R788, our compound for the treatment of rheumatoid arthritis and immune thrombocytopenia purpura (ITP).

For the year ended December 31, 2005, Rigel had revenue of $16.5 million and a net loss of $45.3 million, or a loss per share of $2.07. This compares to revenue of $4.7 million and a net loss of $56.3 million, or a loss per share of $3.12 for the same period in 2004.

As of December 31, 2005, Rigel had cash, cash equivalents and available- for-sale securities of $138.2 million compared to $71.4 million at December 31, 2004 and $127.9 million at September 30, 2005. The $138.2 million includes the $25 million initial payment Rigel received from Serono as part of their Aurora kinase collaboration agreement.

"We have a full pipeline of highly innovative product candidates moving through development, an exceptional team of scientists, clinicians and partners, as well as the financial resources to assess and balance the risks associated with drug development," said James M. Gower, chairman and chief executive officer of Rigel. "In 2006, we will continue to advance our portfolio of product candidates, in particular R788, our lead product candidate. R788`s unique mechanism of action could be helpful in treating intractable autoimmune diseases, and we will test it this year in rheumatoid arthritis and ITP."

Recent Clinical and Business Milestones

The following clinical and business milestones occurred in the fourth quarter of 2005 and beginning of 2006:

* Signed a collaborative agreement with Serono for the development and
commercialization of compounds from Rigel`s Aurora kinase program;
* Filed an investigational new drug (IND) application with the U.S. Food
and Drug Administration for R763;
* Initiated a Phase I double-blind, placebo controlled trial to
investigate the safety and pharmacokinetics of R788 in combination with
methotrexate in rheumatoid arthritis patients;
* Achieved milestones triggering payments from Merck for the selection of
an additional ubiquitin ligase target and from Serono related to the
U.S. Food and Drug Administration`s acceptance of the R763 IND; and
* Completed a Phase II trial of R112 for the treatment of allergic
rhinitis which did not achieve the primary endpoint.

About Rigel (www.rigel.com)


Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases, cancer and viral diseases. Our goal is to move one new product candidate for a significant indication into the clinic each year. We have achieved this goal since 2002. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel`s productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. We have product development programs in rheumatoid arthritis, asthma/allergy and cancer.

This press release contains "forward-looking" statements, including statements related to Rigel`s plans to pursue clinical development of product candidates and the timing thereof, the potential efficacy of product candidates and the sufficiency of financial resources. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "plans," "intends," "expects," "will," "could" and similar expressions are intended to identify these forward-looking statements. There are a number of important factors that could cause Rigel`s results to differ materially from those indicated by these forward-looking statements, including risks associated with the timing and success of pre-clinical studies and clinical trials, as well as other risks detailed from time to time in Rigel`s SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2005. Rigel does not undertake any obligation to update forward-looking statements.

Contact: Jim Welch
Phone: [phone]
Email: [e-mail]


STATEMENTS OF OPERATIONS
(in thousands, except per share amounts)

Three Months Ended Twelve Months Ended
December 31, December 31,
2005 2004 2005 2004
(unaudited) (unaudited)
Revenues:
Contract revenues from
collaborations $6,020 $1,100 $16,526 $4,733

Operating expenses:
Research and development 14,958 12,158 53,505 46,523
General and administrative 3,376 3,676 13,033 12,511
Stock-based compensation
(recovery)/expense (see Note A) (2,228) 168 (2,090) 2,566
Total operating expenses 16,106 16,002 64,448 61,600
Loss from operations (10,086) (14,902) (47,922) (56,867)
Loss on sale/disposal of property
and equipment -- (30) -- (30)
Interest income/(expense), net 1,193 206 2,666 642
Net loss $(8,893) $(14,726) $(45,256) $(56,255)
Net loss per common share, basic
and diluted $(0.36) $(0.75) $(2.07) $(3.12)
Weighted average shares used in
computing net loss per common
share, basic and diluted 24,524 19,544 21,857 18,053


Note A

Stock-based compensation
(recovery)/expense excluded from:
Research and development $(1,576) $137 $(1,467) $2,000
General and administrative (652) 31 (623) 566
$(2,228) $168 $(2,090) $2,566


SUMMARY BALANCE SHEET DATA
(in thousands)

December 31, December 31,
2005 2004(1)
(unaudited)
Cash, cash equivalents and available
for sale securities $138,196 $71,427
Total assets 147,688 78,822
Stockholder`s equity 108,588 52,301

(1) Derived from audited financial statements


SOURCE Rigel Pharmaceuticals, Inc.

Jim Welch of Rigel Pharmaceuticals, Inc., [phone], or [e-mail]


http://www.prnewswire.com


Copyright (C) 2006 PR Newswire. All rights reserved. ********************************************************************** As of Friday, 02-03-2006 23:59, the latest Comtex SmarTrend(SM) Alert, an automated pattern recognition system, indicated a DOWNTREND on 11-29-2005 for RIGL @ $20.82. (C) 2006 Comtex News Network, Inc. All rights reserved.

[nkelchen]

Rigel to Present at BIO CEO & Investor Conference 2006


Rigel Pharmaceuticals, Inc. (PRNewsFoto)

SOUTH SAN FRANCISCO, CA USA 02/17/2005



SOUTH SAN FRANCISCO, Calif., Feb. 8 /PRNewswire-FirstCall/ -- Rigel
Pharmaceuticals, Inc. (Nasdaq: RIGL - News) today announced that James M.
Gower, the company`s chairman and chief executive officer, is scheduled to
present at the BIO CEO & Investor Conference 2006 on Tuesday, February 14th at
3:30 p.m. EST. The conference will be held at the Waldorf=Astoria Hotel in New
York City.
To access the live audio webcast or the subsequent archived recording, log
on to http://www.rigel.com/rigel/events." target="_blank" rel="nofollow ugc noopener">http://www.rigel.com/rigel/events. Please connect to Rigel`s website several
minutes prior to the start of the live webcast to ensure adequate time for any
software download that may be necessary.

About Rigel (http://www.rigel.com)
Rigel is a clinical-stage drug development company that discovers and
develops novel, small-molecule drugs for the treatment of inflammatory
diseases, cancer and viral diseases. Our goal is to move one new product
candidate for a significant indication into the clinic each year. We have
achieved this goal since 2002. Our pioneering research focuses on
intracellular signaling pathways and related targets that are critical to
disease mechanisms. Rigel`s productivity has resulted in strategic
collaborations with large pharmaceutical partners to develop and market our
product candidates. We have product development programs in allergy/asthma,
rheumatoid arthritis and cancer.

This press release contains "forward-looking" statements, including
statements related to Rigel`s plans to pursue clinical development of product
candidates and the timing thereof and the potential efficacy of product
candidates. Any statements contained in this press release that are not
statements of historical fact may be deemed to be forward-looking statements.
Words such as "plans," "intends," "expects" and similar expressions are
intended to identify these forward-looking statements. There are a number of
important factors that could cause Rigel`s results to differ materially from
those indicated by these forward-looking statements, including risks
associated with the timing and success of pre-clinical studies and clinical
trials, as well as other risks detailed from time to time in Rigel`s SEC
reports, including its Quarterly Report on Form 10-Q for the quarter ended
September 30, 2005. Rigel does not undertake any obligation to update forward-
looking statements.

Contact: Jim Welch of Rigel, [phone], or [e-mail].



SOURCE Rigel Pharmaceuticals, Inc.
Web Site: http://www.rigel.com
Photo Notes: NewsCom:
http://www.newscom.com/cgi-bin/prnh/20030226/RIGLLOGO AP Archive:
http://photoarchive.ap.org PRN Photo Desk
[e-mail]

--------------------------------------------------------------------------------

Issuers of news releases and not PR Newswire are solely responsible for the accuracy

[brezlbua]

@ nkelchen

Erstaunlich, dass es zu dem Wert ein paar Beiträge gibt. Aber Du scheinst ja allein auf weiter Flur zu sein.

Die Nachrichtenlage bei RIGL jedenfalls ist ja ganz günstig, viel besser als der Kurs vermuten lässt.

Und jetzt scheint Leben in die Bude zu kommen....bist Du schon dabei?

Gruß und gute Geschäfte

[nkelchen]

[posting]20.250.622 von brezlbua am 17.02.06 10:04:54[/posting]

Hallo bub -

bin schon ein paar Wochen dabei..
Hier ein Link, der mehr zum Thema Rebound enthält:
Thread: Fragen & Antworten...........

wünsche dir auch ein gutes Händchen
Gruss
nk

[brezlbua]

Hi nelkchen :-)

danke für den Link! Wir scheinen eine Vorliebe für ähnliche Kursverläufe zu haben. Bin immer auf der Suche nach Kandidaten, die nach einem Absturz wieder nach oben drehen.

Leider findet man nicht sehr viele Gleichgesinnte. Die meisten rennen viel lieber alle gemeinsam in die gleiche Richtung

Gruß und gute Geschäfte

b

[nkelchen]

[posting]20.263.710 von brezlbua am 17.02.06 20:44:15[/posting]

bin auch gespannt, wie es am Jahresende aussieht..

im Moment macht RIGL ja richtig Freude!


nk
*schönes Wochenende*

[nkelchen]

[posting]20.263.827 von nkelchen am 17.02.06 20:51:58[/posting]

heute durch die 10€ Marke!?
-----------------------------------

Press Release Source: Rigel Pharmaceuticals, Inc.


Rigel Announces Completion of R788 Plus Methotrexate Drug Interaction Study in Patients with Rheumatoid Arthritis
Wednesday February 22, 7:30 am ET
Company to Initiate Further Clinical Studies of R788 in Rheumatoid Arthritis and in Immune Thrombocytopenic Purpura Later This Year


SOUTH SAN FRANCISCO, Calif., Feb. 22 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL - News) today announced preliminary data from a Phase I double-blind, placebo controlled trial to investigate the safety and pharmacokinetics of R788, an oral syk kinase inhibitor, in combination with methotrexate in rheumatoid arthritis (RA) patients. The data demonstrated that R788 was well tolerated when given in combination with methotrexate and had no significant adverse pharmacokinetic interactions. The company also announced plans to initiate separate clinical efficacy studies with R788, in RA and in Immune Thrombocytopenic Purpura (ITP), in the second half of 2006.
ADVERTISEMENT


"New, effective therapeutic options in RA are greatly needed since current treatments have potentially significant limitations," stated Elliott B. Grossbard, M.D., senior vice president of medical development at Rigel. "We are pursuing R788 in autoimmune diseases such as RA and ITP because it has been shown to be a potent and selective inhibitor of syk kinase, which may play a key role in autoimmune diseases."

The Phase I study enrolled patients verified to suffer from RA and who were receiving methotrexate treatment. There were no unanticipated adverse events and pharmacokinetic analysis suggests that there is no adverse interaction with the two agents.

About R788

R788 is a novel, oral syk kinase inhibitor that blocks the activation of mast cells, macrophages and B cells that promote swelling and an inflammatory response. It is being developed initially to treat RA. Phase I trial results have demonstrated that R788 is well-tolerated and showed good pharmaceutical properties. Earlier Phase I studies generated valuable pharmacokinetic/pharmacodynamic data establishing a strong correlation between drug plasma levels and the inhibition of the drug target. In preclinical studies, Rigel`s compound greatly diminished the swelling and tissue destruction associated with RA. In addition, in a murine model of ITP, the drug increased platelet counts significantly.

Rheumatoid Arthritis: Current Treatments and Market Opportunity

Approximately 2.1 million people in the U.S. suffer from RA and the worldwide market for innovative RA drugs is projected to reach $10 billion by 2008. RA is a chronic inflammatory disease that affects multiple tissues, but typically produces its most pronounced symptoms in the joints. It is often progressive and debilitating, preventing people from living a symptom-free life. Ultimately the chronic inflammation of joints leads to the destruction of the soft tissue and erosion of the articular surfaces of the bone.

The current treatment options for RA have potentially significant side effects and other shortfalls, including gastrointestinal complications and kidney damage. Some RA patients currently receive multiple drugs depending on the extent and aggressiveness of the disease. Most RA patients require some form of DMARD -- including methotrexate, an anti-cancer agent, or TNF-blocking agents such as Enbrel®. The TNF-blocking agents only inhibit the inflammatory mediator TNF, and are all delivered via injection. Rigel believes that there is a significant opportunity for an oral DMARD that can be used earlier in the course of the disease, preventing its progression prior to major bone and cartilage destruction; this is the product goal for R788 in RA.

About Rigel (www.rigel.com)

Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases, cancer and viral diseases. Our goal is to move one new product candidate for a significant indication into the clinic each year. We have achieved this goal since 2002. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel`s productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. We have product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia, asthma and allergy, as well as in cancer.

This press release contains "forward-looking" statements, including statements related to Rigel`s plans to pursue clinical development of product candidates and the timing thereof and the potential efficacy and safety of product candidates, and the opportunity of a DMARD. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "plans," "intends," "expects," "believes," "goal," "suggests," and similar expressions are intended to identify these forward-looking statements. There are a number of important factors that could cause Rigel`s results to differ materially from those indicated by these forward-looking statements, including risks associated with the timing and success of pre-clinical studies and clinical trials, as well as other risks detailed from time to time in Rigel`s SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2005. Rigel does not undertake any obligation to update forward-looking statements.


CONTACT:
Raul Rodriguez
[phone]
[e-mail]

MEDIA CONTACT:
Carolyn Bumgardner Wang
WeissComm Partners, Inc.
[phone]
[e-mail]


nk

[nkelchen]

die 9 scheint zu halten,
das kann ja noch schön werden...



nk

[nkelchen]

[posting]20.634.612 von nkelchen am 11.03.06 19:09:14[/posting]

heute über die 10?!

Press Release Source: Rigel Pharmaceuticals, Inc.


Rigel Granted Key Patents in Immunology, Virology and Oncology
Tuesday March 21, 7:30 am ET
29 Patents Issued in Past 24 Months


SOUTH SAN FRANCISCO, Calif., March 21 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL - News) today announced that it has been awarded 29 patents since February 2004. Specifically, Rigel was granted six patents in immunology, five patents related to its ubiquitin ligase technology, four patents related to hepatitis-C (HCV), six patents in oncology, four patents towards its library screening technology, and four patents in Fluorescence- Activated Cell Sorter (FACS) technology. Rigel is ranked as one of the top 15 biotech companies in the February 10, 2006 San Francisco Business Times` annual listing of the largest biotech patent recipients in the San Francisco Bay Area, based on the number of patents assigned in 2005.
ADVERTISEMENT


"Rigel remains on the forefront of ligase research, and has significant research and development expertise in immunology, virology and oncology where we have been identifying and developing novel, small-molecule drugs," said Donald G. Payan, M.D., executive vice president and chief scientific officer of Rigel. "The large number of patents we have received over the past year exemplifies our productivity in these key disease areas."

Of particular interest are several broadly enabling patent estates that have been issued to Rigel and cover key areas of drug discovery. These include:

Ligase

Rigel`s ligase patent estate includes five issued patents and one allowed patent in the United States. The patents cover methods for identifying and/or measuring ubiquitin ligase activity in any disease state and screening for agents that modulate their activity using any of the major enzymes in the ligase pathway as well as particular enzymes. This means the patented subject matter covers screens using any ubiquitin activating enzyme (E1), any ubiquitin conjugating enzyme (E2) or any ligase (E3) as the drug target. Rigel has had two major collaborations based on these proprietary screens.

IRES

Rigel has several issued patents covering screening for antiviral agents where IRES (internal ribozyme entry site) is the drug target. The IRES controls viral translation and protein synthesis, making it an important drug target.

FACS

Rigel`s FACS patent estate covers patents issued in both the U.S. and Europe. FACS assays are used to investigate gene expression and characterize a given drug`s impact on diseased or healthy cells, and are capable of measuring multiple parameters at one time. Rigel`s patents cover FACS assays that measure a minimum of three parameters, which affect different disease states such as cancer and allergy-related disorders, and the cells` response to drugs.

Rigel is pursuing opportunities to license these patent(s) to potential partners that are working in these areas. For more information please contact Rigel`s Business Development and Licensing Department at: [e-mail] or 650-624-1142.

About Rigel (www.rigel.com)

Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases, cancer and viral diseases. Our goal is to move one new product candidate for a significant indication into the clinic each year. We have achieved this goal since 2002. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel`s productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. We have product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia, and asthma and allergy, as well as in cancer.

This press release contains "forward-looking" statements, including statements related to the potential value of Rigel`s patent portfolio or its development programs, Rigel`s plans to pursue clinical development of product candidates and the timing thereof and the potential efficacy and safety of product candidates. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "plans," "intends," "expects," "believes," and similar expressions are intended to identify these forward-looking statements. There are a number of important factors that could cause Rigel`s results to differ materially from those indicated by these forward-looking statements, including risks associated with the timing and success of pre-clinical studies and clinical trials, as well as other risks detailed from time to time in Rigel`s SEC reports, including its Annual Report on Form 10-K for the year ended December 31, 2005. Rigel does not undertake any obligation to update forward-looking statements.


Contact: Raul Rodriguez
Phone: [phone]
Email: [e-mail]

Media Contact: Carolyn Bumgardner Wang, WeissComm Partners, Inc.
Phone: [phone]
Email: [e-mail]




--------------------------------------------------------------------------------
Source: Rigel Pharmaceuticals, Inc.

[nkelchen]

Antwort auf Beitrag Nr.: 20.888.115 von nkelchen am 21.03.06 13:51:44

Neues AD high, bei 10,40.
So langsam wird es was...
nk

[nkelchen]

hätte nicht gedacht, dass das Teil so sauber läuft...
noch 50Cent
und die ersten 50% sind eingetütet!


nk

[nkelchen]

[nkelchen]

Antwort auf Beitrag Nr.: 21.033.151 von nkelchen am 31.03.06 18:21:57

nächster Anlauf auf die 12$ Marke.



nk

[nkelchen]

Antwort auf Beitrag Nr.: 21.283.367 von nkelchen am 22.04.06 16:45:59

war nix mit 12$
habe meine Posi heute zu 10,10$ aufgelöst-
der Chart gefällt mir nicht mehr...
nk